Nonetheless, none of the MR-PheWAS hits are acute life-threatening conditions; thus, targeting ORM1 or OVGP1 in MM appears feasible from a safety standpoint, provided that any chronic implications (vision-related, pain-related, metabolic) are managed. This evidence concerns the gene OVGP1 and Miyoshi myopathy.